HGS in search for cancer, immunology drugs acquisitions
HGS is set to start selling Benlysta along with its partner, London-based GlaxoSmithKline, if the USFDA clears the medicine by 10 March, reported Bloomberg.com. Benlysta prevents the production
WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.